Northern Trust Corp lifted its stake in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 38.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,552 shares of the biotechnology company’s stock after acquiring an additional 11,176 shares during the period. Northern Trust Corp owned 0.28% of Eiger Biopharmaceuticals worth $495,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently modified their holdings of the company. 683 Capital Management LLC boosted its stake in shares of Eiger Biopharmaceuticals by 51.2% in the second quarter. 683 Capital Management LLC now owns 295,285 shares of the biotechnology company’s stock worth $3,602,000 after acquiring an additional 100,000 shares during the period. GMT Capital Corp bought a new position in Eiger Biopharmaceuticals during the second quarter valued at approximately $3,459,000. Millennium Management LLC bought a new position in Eiger Biopharmaceuticals during the second quarter valued at approximately $871,000. Ardsley Advisory Partners bought a new position in Eiger Biopharmaceuticals during the second quarter valued at approximately $305,000. Finally, Renaissance Technologies LLC boosted its stake in Eiger Biopharmaceuticals by 40.4% during the second quarter. Renaissance Technologies LLC now owns 230,229 shares of the biotechnology company’s stock valued at $2,809,000 after buying an additional 66,200 shares during the last quarter. 51.62% of the stock is owned by institutional investors.
A number of equities analysts recently commented on EIGR shares. Wedbush set a $55.00 price target on Eiger Biopharmaceuticals and gave the company a “buy” rating in a research note on Friday, October 19th. Oppenheimer set a $26.00 price target on Eiger Biopharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 18th. ValuEngine raised Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 17th. LADENBURG THALM/SH SH set a $28.00 price target on Eiger Biopharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 17th. Finally, Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $12.00 price target for the company in a research note on Monday, October 15th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $29.71.
Shares of Eiger Biopharmaceuticals stock opened at $11.44 on Friday. Eiger Biopharmaceuticals Inc has a 12 month low of $7.46 and a 12 month high of $18.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.59 and a quick ratio of 4.59.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.43). On average, equities research analysts forecast that Eiger Biopharmaceuticals Inc will post -3.51 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Eiger Biopharmaceuticals Inc (EIGR) Shares Bought by Northern Trust Corp” was originally published by BBNS and is owned by of BBNS. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://baseballnewssource.com/2018/12/08/eiger-biopharmaceuticals-inc-eigr-shares-bought-by-northern-trust-corp/3064228.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Further Reading: Balance Sheet
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.